Gonadotropin-releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome

Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation

“…An additional factor favoring multifollicular development in the presence of the antagonist is the finding that there was a statistically significant reduction of premature luteinization risk in cycles treated with antagonist compared with the control group (1.7% vs. 17.5%). This finding is in accordance with other studies (13,17) and allows a policy of expectant management to obtain multifollicular development in antagonist IUI cycles. Furthermore, the significant reduction in the incidence of premature luteinization could be an independent factor favoring increased pregnancy rates in the antagonist group (13).…”

Effect of gonadotropin-releasing hormone antagonists on intrauterine insemination cycles in women with polycystic ovary syndrome: a meta-analysis

“…Seven studies were excluded after examination of the manuscripts: of these, three were about the effect of GnRH-ant in the in vitro fertilization cycle [10][11][12], three were studies that did not include patients with PCOS [13][14][15] and one was a clinical review [16]. Finally, only two randomized studies met the final inclusion criteria and contained a total of 333 cycles [17,18]. A flowchart of the studies included is provided in Figure 1.…”

“…Gonadotropin therapy is indicated for women with anovulatory PCOS who are resistant to CC. However, approximately 26% of all patients with PCOS undergoing COS with gonadotropin are at risk of premature luteinization [17], which has been previously demonstrated to be detrimental to the chances of pregnancy or to result in a higher than normal rate of miscarriage [20,21]. Previous studies on COH/IVF treatment have indicated that GnRH-ant treatment in the late follicular phase could effectively suppress the premature LH surge [22,23].…”

The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study

“…In the recently published randomized controlled study in women with PCOS, Ertunc et al concluded that Ganirelix use in r-FSH OI/IUI resulted in higher frequency of monofollicular development, less premature luteinization, and less cycle cancellation (25). However, there was no significant difference in pregnancy rates, as they showed a per-cycle CPR of 10.7% in the control group and 15.2% in the group using Ganirelix in a flexible protocol.…”